Company news: Boehringer Ingelheim, GlaxoSmithKline

Share this article:
Boehringer Ingelheim's foray into oncology meds now includes a five-year collaboration agreement with personalized medicine specialist Horizon Discovery. The agreement gives Boehringer access to its Discovery Toolbox, which will profile the drug maker's compounds, and Genesis, Horizon's genome editing technology to help develop human isogenic disease model cells. Horizon said the technology will help develop “high quality cell lines” that model disease-causing mutations.

Months after its Human Genome Sciences buy, GlaxoSmithKline has submitted a BLA for albiglutide, a pipeline diabetes 2 therapy. GSK gained full ownership of the therapy with its HGS acquisition, along with ownership of Benlysta and darapladib. The experimental drug, which is being developed as a weekly shot, is a GLP-1 agonist, much like Amylin's weekly Bydureon.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.